Journal of the Korean Society of Food Science and Nutrition (한국식품영양과학회지)

The Korean Society of Food Science and Nutrition (한국식품영양과학회)
권호 표지
DOI QR코드

DOI QR Code

The Hepatoprotective Effect of Acanthopanax senticosus Fermentation Products in Fatty Liver Model

지방간 모델에서 가시오가피 발효물의 간 기능 개선 효과

  • Received : 2013.09.10
  • Accepted : 2013.10.17
  • Published : 2014.01.31
Download PDF
⟨ Previous Next ⟩

Abstract

We demonstrated that Acanthopanax senticosus fermentation products (FM-5111 and FM-5131) administered to rats functionally protect against DL-ethionine-induced and ethanol-induced fatty liver models. In DL-ethionine-induced fatty liver models, the serum concentrations of aspartate aminotransferase (AST), as well as liver concentrations of triglyceride and total lipid against the control decreased in FM-5111 and FM-5131 treated rats. In ethanol-induced fatty liver models, FM-5111 and FM-5131 treated rats showed a decrease in the liver concentrations of triglyceride and total lipid in ethanol-induced fatty liver models. There were no significant differences in the serum concentrations of AST and alanine aminotransferase in FM-5111 and FM-5131 treated rats. Additionally, FM-5111-, or FM-5131-treated rats showed no significant differences in the body weight gain between the control. These results indicate that Acanthopanax senticosus fermentation products might have protective effects against DL-ethionine-induced and ethanol-induced fatty liver models.

본 연구에서는 두 종류의 가시오가피 발효물 추출물(FM-5111, FM-5131)에 대한 지방간 예방 및 개선 효능을 검토하였다. 그 결과 FM-5111, FM-5131 모두 ethionine과 ethanol 지방간 모델에서 간 손상의 지표인 AST의 수치를 감소시키며, 간 내 총 지질량과 중성지방 함유량을 감소시키는 효능을 보이고 있다. 특히 간 내 총 지질량과 중성지방 함유량의 감소 정도로 보았을 때, ethanol 지방간 모델에서 더욱 두드러진 효능을 보이고 있다. 따라서 FM-5111과 FM-5131은 비알코올성 지방간 형성을 예방하고 알코올에 의해 형성된 지방간을 개선하는 효능을 가지고 있으며, 비알코올성 지방간과 알코올성 지방간 모델에서 간 손상 등을 억제하는 것으로 판단된다.

Keywords

References

  1. Salgado Júnior W, Santos JS, Sankarankutty AK, de Castro e Silva O. 2006. Nonalcoholic fatty liver disease and obesity. Acta Cir Bras 21 (suppl. 1): 72-78. https://doi.org/10.1590/S0102-86502006000700017
  2. Younossi ZM. 1999. Nonalcoholic fatty liver disease. Curr Gastroenterol Rep 1: 57-62. https://doi.org/10.1007/s11894-999-0088-1
  3. Stewart S, Jones D, Day CP. 2001. Alcoholic liver disease: new insights into mechanisms and preventative strategies. Trends Mol Med 7: 408-413. https://doi.org/10.1016/S1471-4914(01)02096-2
  4. Purohit V, Russo D, Coates PM. 2004. Role of fatty liver, dietary fatty acid supplements, and obesity in the progression of alcoholic liver disease: introduction and summary of the symposium. Alcohol 34: 3-8. https://doi.org/10.1016/j.alcohol.2004.06.008
  5. Caldwell SH, Harris DM, Patrie JT, Hespenheide EE. 2002. Is NASH underdiagnosed among African Americans? Am J Gastroenterol 97: 1496-1500. https://doi.org/10.1111/j.1572-0241.2002.05795.x
  6. Lieber CS. 2004. Alcoholic fatty liver: its pathogenesis and mechanism of progression to inflammation and fibrosis. Alcohol 34: 9-19. https://doi.org/10.1016/j.alcohol.2004.07.008
  7. Lakshman MR. 2004. Some novel insights into the pathogenesis of alcoholic steatosis. Alcohol 34: 45-48. https://doi.org/10.1016/j.alcohol.2004.08.004
  8. Mallov S, Bloch JL. 1956. Role of hypophysis and adrenals in fatty infiltration of liver resulting from acute ethanol intoxication. Am J Physiol 184: 29-34.
  9. Papatheodoridis GV, Chrysanthos N, Cholongitas E, Pavlou E, Apergis G, Tiniakos DG, Andrioti E, Theodossiades G, Archimandritis AJ. 2009. Thrombotic risk factors and liver histologic lesions in non-alcoholic fatty liver disease. J Hepatol 51: 931-938. https://doi.org/10.1016/j.jhep.2009.06.023
  10. Ko JS, Yoon JM, Yang HR, Myung JK, Kim H, Kang GH, Cheon JE, Seo JK. 2009. Clinical and histological features of nonalcoholic fatty liver disease in children. Dig Dis Sci 54: 2225-2230. https://doi.org/10.1007/s10620-009-0949-3
  11. Bijl N, Sokolović M, Vrins C, Langeveld M, Moerland PD, Ottenhoff R, van Roomen CP, Claessen N, Boot RG, Aten J, Groen AK, Aerts JM, van Eijk M. 2009. Modulation of glycosphingolipid metabolism significantly improves hepatic insulin sensitivity and reverses hepatic steatosis in mice. Hepatology 50: 1431-1441. https://doi.org/10.1002/hep.23175
  12. Mehta K, Van Thiel DH, Shah N, Mobarhan S. 2002. Nonalcoholic fatty liver disease: pathogenesis and the role of antioxidants. Nutr Rev 60: 289-293. https://doi.org/10.1301/002966402320387224
  13. Duvnjak M, Lerotic I, Barsic N, Tomasic V, Virovic Jukic L, Velagic V. 2007. Pathogenesis and management issues for non-alcoholic fatty liver disease. World J Gastroenterol 13: 4539-4550.
  14. Brekhman II. 1960. A new medicinal plant of the family Araliaceae the spiny Eleutherococcus. Izv Sibir Otdel Akad Nauk USSR 9: 113-120.
  15. Ovodov YS, Ovodova RG, Solov'eva TF, Elyakov GB, Kochetkov NK. 1965. The glycosides of Eleutherococcus senticosus Max. I. Isolation and some properties of eleutheroside B and E. Khim Prir Soedin 1: 1-4.
  16. Halstead BW, Hood LL. 1984. An introduction to adaptogenic medicine. In Eleutherococcus senticosus: Siberian ginseng. Origental Healing Arts Institute, Bristol, CT, USA. p 1-94.
  17. Hirata F, Fujita K, Ishikura Y, Hosoda K, Ishikawa H, Nakamura H. 1996. Hypocholesterolemic effect of sesame lignan in humans. Atherosclerosis 122: 135-136. https://doi.org/10.1016/0021-9150(95)05769-2
  18. Lee KH, Jeong H, Kim YI, Kim BK. 1991. Production of antihypertensive constituents from Ganoderma lucidum IY005 by fermentation using industrial wastes. Korean J Mycol 19: 79-84.
  19. Oh SI, Lee MS. 2005. Antioxidative and antimutagenic effects of Ganoderma lucidum krast extracts. Korean J Food & Nutr 18: 54-62.
  20. Bae HS, Kang SK, Shin IS, Woo SK, Kim YJ, Kim MA, Ra JC. 2009. The effects of extracts mixture drink from Inonotus obliquus, Phellinus linteus and Ganoderma lucidum on hematopoietic stem cells and lymphocyte subset of blood in human. J Fd Hyg Safety 24: 78-85.
  21. Lee SY, Rhee HM. 1990. Cardiovascular effects of mycelium extract of Ganoderma lucidum: inhibition of sympathetic outflow as a mechanism of its hypotensive action. Chem Pharm Bull 38: 1359-1364. https://doi.org/10.1248/cpb.38.1359
  22. Adachi Y, Ohno N, Ohsawa M, Oikawa S, Yadomae T. 1990. Macrophage activation in vitro by chemically crosslinked (1$\rightarrow$3)-beta-D-glucans. Chem Pharm Bull 38: 988-992. https://doi.org/10.1248/cpb.38.988
  23. Usui T, Iwasaki Y, Hayashi K, Mizuno T, Tanaka M, Shinkai K, Arakawa M. 1981. Antitumor activity of water-soluble beta-D-glucan elaborated by Ganoderma applanatum. Agric Biol Chem 45: 323-326. https://doi.org/10.1271/bbb1961.45.323
  24. Sone Y, Okuda R, Wada N, Kishida E, Misaki A. 1985. Structures and antitumor activities of the polysaccharides isolated from fruiting body and the growing culture of mycelium of Ganoderma lucidum. Agric Biol Chem 49: 2641-2653. https://doi.org/10.1271/bbb1961.49.2641
  25. Frings CS, Dunn RT. 1970. A colorimetric method for determination of total serum lipids based on the sulfo-phospho-vanilin reaction. Am J Clin Pathol 53: 89-91.
  26. Uchiyama M, Mihara M. 1978. Determination of malondialdehyde precursor in tissues by thiobarbituric acid test. Anal Biochem 86: 271-278. https://doi.org/10.1016/0003-2697(78)90342-1
  27. Suriawinate AA, Thung SN. 2006. Acute and chronic hepatitis. Seminars in Diagnostic Pathology 23: 132-148. https://doi.org/10.1053/j.semdp.2006.11.001
  28. Wang J, Atchison RW, Walpusk J, Jaffe R. 2001. Echovirus hepatic failure in infancy: report of four cases with speculation on the pathogenesis. Pediatr Dev Pathol 4: 454-460. https://doi.org/10.1007/s10024001-0043-0
  29. Mira L, Maia L, Barreira L, Manso CF. 1995. Evidence for free radical generationdue to NADH oxidation by aldehyde oxidase during ethanol metabolism. Arch Biochem Biophys 318: 53-58. https://doi.org/10.1006/abbi.1995.1203
  30. Adams LA, Angulo P. 2005. Recent concepts in non-alcoholic fatty liver disease. Diabet Med 22: 1129-1133. https://doi.org/10.1111/j.1464-5491.2005.01748.x
  31. Canbay A, Bechmann L, Gerken G. 2007. Lipid metabolism in the liver. Z Gastroenterol 41: 35-41.

Cited by

  1. Acute and subchronic (13-week) toxicity of fermented Acanthopanax koreanum extracts in Sprague Dawley rats vol.77, 2016, https://doi.org/10.1016/j.yrtph.2016.02.017
  2. Seven Cases of Wart treated with MY1-Hwan vol.39, pp.4, 2018, https://doi.org/10.13048/jkm.18045
  3. 복합생약 HO-Series의 숙취개선 임상적 유용성 평가 vol.51, pp.4, 2014, https://doi.org/10.22889/kjp.2020.51.4.278